Table I.
Subject characteristics (n =7559).
| Characteristic | Therapy type and era
|
Total | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre-rituximab
|
Post rituximab
|
|||||||||||
| ABC, n (%) | Non-ABC, n (%) | No therapy, n (%) | Era total, n (%) | ABC w/R, n (%) | ABC w/o R, n (%) | Non-ABC w/R, n (%) | Non-ABC w/o R, n (%) | No therapy, n (%) | R only, n (%) | Era total, n (%) | ||
| Total | 2193 | 307 | 1284 | 3784 | 968 | 1216 | 96 | 153 | 1228 | 114 | 3775 | 7559 |
| Age 66–70 | 577 (26) | 52 (17) | 169 (13) | 798 (21) | 244 (25) | 284 (23) | 14 (15) | 17 (11) | 128 (10) | 12 (11) | 699 (19) | 1497 (20) |
| Age 71–75 | 658 (30) | 78 (25) | 229 (18) | 965 (26) | 303 (31) | 334 (27) | 21 (22) | 35 (23) | 213 (17) | 17 (15) | 923 (24) | 1888 (25) |
| Age 76–80 | 568 (26) | 78 (25) | 288 (22) | 934 (25) | 239 (25) | 345 (28) | 22 (23) | 39 (25) | 282 (23) | 19 (17) | 946 (25) | 1880 (25) |
| Age 81–84 | 248 (11 | 59 (19) | 220 (17) | 527 (14) | 119 (12) | 150 (12) | 18 (19) | 30 (20) | 229 (19) | 24 (21) | 570 (15) | 1097 (15) |
| Age 85+ | 142 (6) | 40 (13) | 378 (29) | 560 (15) | 63 (7) | 103 (8) | 21 (22) | 32 (21) | 376 (31) | 42 (37) | 637 (17) | 1197 (16) |
| White | 2051 (94) | 279 (91) | 1159 (90) | 3489 (92) | 899 (93) | 1130 (93) | ★ | 136 (89) | 1106 (90) | ★ | ★ | 6961 (92) |
| Black | 55 (3) | ★ | 51 (4) | ★ | 24 (2) | 36 (3) | ★ | ★ | 49 (4) | ★ | ★ | 231 (3) |
| Asian | 63 (3) | 14 (5) | 62 (5) | 139 (4) | 28 (3) | 39 (3) | ★ | ★ | 43 (4) | ★ | 120 (3) | 259 (3) |
| Other | 24 (1) | ★ | 12 (1) | ★ | 17 (2) | 11 (1) | ★ | ★ | 30 (2) | ★ | ★ | 108 (1) |
| Stage I | 700 (32) | 89 (29) | 442 (34 | 1231 (33) | 252 (26) | 395 (32) | 21 (22) | 43 (28) | 386 (31 | 36 (32) | 1133 (30) | 2364 (31) |
| Stage II | 438 (20) | 63 (21) | 188 (15) | 689 (18) | 196 (20) | 252 (21) | 19 (20) | 36 (24) | 191 (16) | 21 (18) | 715 (19) | 1404 (19) |
| Stage III | 310 (14) | 36 (12) | 126 (10) | 472 (12) | 158 (16) | 185 (15) | ★ | ★ | 141 (11) | ★ | 532 (14) | 1004 (13) |
| Stage IV | 629 (29) | 102 (33) | 441 (34 | 1172 (31) | 314 (32) | 322 (26) | 25 (26) | 46 (30) | 403 (33 | 39 (34) | 1149 (30) | 2321 (31) |
| Unstaged | 116 (5) | 17 (6) | 87 (7) | 220 (6) | 48 (5) | 62 (5) | ★ | ★ | 107 (9) | ★ | 246 (7) | 466 (6) |
| Male | 998 (46) | 144 (47) | 543 (42 | 1685 (45) | 460 (48) | 541 (44) | 53 (55) | 79 (52) | 562 (46 | 47 (41) | 1742 (46) | 3427 (45) |
| Female | 1195 (54) | 163 (53) | 741 (58) | 2099 (55) | 508 (52) | 675 (56) | 43 (45) | 74 (48) | 666 (54) | 67 (59) | 2033 (54) | 4132 (55) |
| Inpatient claims comorbidity 0 | 1978 (90) | 266 (87) | 1013 (79) | 3257 (86) | 868 (90) | 1088 (89) | 71 (74) | 126 (82) | 938 (76) | 93 (82) | 3184 (84) | 6441 (85) |
| Inpatient claims comorbidity 1+ | 215 (10) | 41 (13) | 271 (21) | 527 (14) | 100 (10) | 128 (11) | 25 (26) | 27 (18) | 290 (24) | 21 (18) | 591 (16) | 1118 (15) |
| Physician claims comorbidity 0 | 1802 (82) | 241 (79) | 981 (76) | 3024 (80) | 732 (76) | 949 (78) | 71 (74) | 101 (66) | 918 (75) | 80 (70) | 2851 (76) | 5875 (78) |
| Physician claims comorbidity 1+ | 391 (18) | 66 (22) | 303 (24) | 760 (20) | 236 (24) | 267 (22) | 25 (26) | 52 (34) | 310 (25) | 34 (30) | 924 (24) | 1684 (22) |
★
Cell size suppressed to protect confidentiality.
ABC, anthracycline-based chemotherapy; R, rituximab; w/, with; w/o, without.